Skip to main content

Participant information and resources

Our volunteers make ground-breaking research possible. By joining the AIBL study, you can help us improve the diagnosis of Alzheimer’s disease and discover treatments and lifestyle factors that can prevent or delay the disease.

Support for current volunteers

Participate in the AIBL study

Be part of something life-changing

The AIBL study uses biomarkers in the body to identify Alzheimer’s disease risks in a person. Participating in this research may help you detect early brain changes and identify your risk of developing Alzheimer's disease.

The ongoing success of our research relies on the generosity of volunteers. Your involvement helps researchers develop earlier detection methods and treatments.
Stock photo of female patient discussing health complaints with doctor in a medical exam.

What to expect

Participants are invited to complete a study visit every 12–18 months. Study visits include:

  • a fasting blood test
  • brief interview
  • neuropsychological testing
  • questionnaires about daily functioning, medical history, family history and mood and thinking skills.

Visits take approximately 2.5–3 hours to complete. Participants are also invited to participate in separate imaging visits (MRI brain and PET scans) and undergo a voluntary lumbar puncture.

Find out if you’re eligible

If you are over 65 and worried about your memory or have a diagnosed memory problem, you may be eligible to participate in our study.

If you live in Melbourne or Perth and would like more information about participating in this study, please contact your local AIBL representative.
Map of Australia showing AIBL locations in Perth and Melbourne along with their contact details.

You can also register your interest through the Australian Dementia Network (ADNet) to participate in clinical trials for promising Alzheimer’s disease therapies.

News and events

Get the latest global news about dementia research.


Explore innovations and clinical developments in Alzheimer’s disease.

Stay up to date with the latest news from the AIBL study.